Showing 221-230 of 7651 results for "".
Colloidal Oatmeal in the Treatment of Atopic Dermatitis
https://practicaldermatology.com/topics/atopic-dermatitis/colloidal-oatmeal-in-the-treatment-of-atopic-dermatitis/23338/Is this plant-based intervention an effective treatment alternative?The Shape of Atopic Dermatitis
https://practicaldermatology.com/columns/clinical-focus-1/the-shape-of-atopic-dermatitis/23037/What do we really mean when we talk about flares or waxing and waning presentations?Chitotriosidase: Providing Confirmation of Sarcoidosis When ACE Fails
https://practicaldermatology.com/topics/clinical-case-reports/chitotriosidase-providing-confirmation-of-sarcoidosis-when-ace-fails/26642/Chitotriosidase: Providing Confirmation of Sarcoidosis When ACE FailsTazarotene Lotion for Acne
https://practicaldermatology.com/topics/acne-rosacea/tazarotene-lotion-for-acne/23388/Tazarotene Lotion 0.045% offers dermatologists a new option that is effective and well tolerated for treating acne.DermwireTV: Rinvoq Approved for Pediatric Psoriatic Arthritis; J&J Acquires Novel AD Candidate
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-rinvoq-approved-for-pediatric-psoriatic-arthritis/26269/In this week's DermwireTV, the FDA approves Rinvoq for pediatric psoriatic arthritis; Johnson & Johnson acquires an AD candidate for $1.25 billion; and the president of Acclaro Medical discusses the latest FDA clearance of its Ultraclear Laser.Hilary Baldwin, MD: Perspective on the FDA Citizen's Petition for Acne Products with Benzoyl Peroxide (BPO)
https://practicaldermatology.com/topics/acne-rosacea/hilary-baldwin-md-perspective-fda-citizens-petition-acne-products-benzoyl-peroxide-bpo/24171/Neal Bhatia, MD, chief medical editor of Practical Dermatology® talks to Hilary E. Baldwin, MD about a new report from an independent laboratory that finds benzene can form at unacceptably high levels in both over-the-counter and prescription medications that contain benzoyl peroxide.First Medication for Severe Frostbite; Biosimilar to Humira with Interchangeability Status Approved; Two Late-Stage AD Candidates Advance
https://practicaldermatology.com/series/dermwire-tv/first-medication-for-severe-frostbite-biosimilar-to-humira-with-interchangeability-status-approved-two-late-stage-ad-candidates-advance/20267/In this episode of DermWireTV, the first medication to treat severe frostbite is approved by the FDA; the first high-concentration biosimilar to Humira with interchangeability status will soon be available in the US; and two companies with late-stage atopic dermatitis candidates provide key updates.Can AI and Digital Innovation Improve the Patient Experience?
https://practicaldermatology.com/topics/practice-management/can-ai-and-digital-innovation-improve-the-patient-experience/23964/Embrace AI and how it can help improve points of contact with your patients.DermWireTV: Zoryve Approved; New SDPA President; Project Determi-Nation; Stelara for Pediatric PsA
https://practicaldermatology.com/topics/psoriasis/dermwiretv-zoryve-approved-new-sdpa-president-project-determi-nation-stelara-for-pediatric-psa/20115/FDA has approved Zoryve from Arcutis Biotherapeutics for the treatment of plaque psoriasis, including intertriginous areas, in patients 12 years of age or older. The novel formulation of roflumilast cream 0.3% is indicated for once-daily application. Stelara (ustekinumab) from Janssen is now approveConsidering a Role for Oral JAK Inhibitors in AD Care
https://practicaldermatology.com/topics/atopic-dermatitis/considering-a-role-for-oral-jak-inhibitors-in-ad-care/23745/The newest class of treatments for AD expands the possibilities to achieve and maintain skin clearance.